Granulomatosis with Polyangiitis Drug Market
1 Study Coverage
1.1 Granulomatosis with Polyangiitis Drug Product Introduction
1.2 Market by Type
1.2.1 Global Granulomatosis with Polyangiitis Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Benralizumab
1.2.3 Avacopan
1.2.4 Rituximab Biosimilar
1.2.5 Others
1.3 Market by Application
1.3.1 Global Granulomatosis with Polyangiitis Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Granulomatosis with Polyangiitis Drug Sales Estimates and Forecasts 2017-2028
2.2 Global Granulomatosis with Polyangiitis Drug Revenue Estimates and Forecasts 2017-2028
2.3 Global Granulomatosis with Polyangiitis Drug Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Granulomatosis with Polyangiitis Drug Sales by Region
2.4.1 Global Granulomatosis with Polyangiitis Drug Sales by Region (2017-2022)
2.4.2 Global Sales Granulomatosis with Polyangiitis Drug by Region (2023-2028)
2.5 Global Granulomatosis with Polyangiitis Drug Revenue by Region
2.5.1 Global Granulomatosis with Polyangiitis Drug Revenue by Region (2017-2022)
2.5.2 Global Granulomatosis with Polyangiitis Drug Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Granulomatosis with Polyangiitis Drug Sales by Manufacturers
3.1.1 Global Top Granulomatosis with Polyangiitis Drug Manufacturers by Sales (2017-2022)
3.1.2 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Granulomatosis with Polyangiitis Drug in 2021
3.2 Global Granulomatosis with Polyangiitis Drug Revenue by Manufacturers
3.2.1 Global Granulomatosis with Polyangiitis Drug Revenue by Manufacturers (2017-2022)
3.2.2 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Granulomatosis with Polyangiitis Drug Revenue in 2021
3.3 Global Granulomatosis with Polyangiitis Drug Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Granulomatosis with Polyangiitis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Granulomatosis with Polyangiitis Drug Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Granulomatosis with Polyangiitis Drug Sales by Type
4.1.1 Global Granulomatosis with Polyangiitis Drug Historical Sales by Type (2017-2022)
4.1.2 Global Granulomatosis with Polyangiitis Drug Forecasted Sales by Type (2023-2028)
4.1.3 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2017-2028)
4.2 Global Granulomatosis with Polyangiitis Drug Revenue by Type
4.2.1 Global Granulomatosis with Polyangiitis Drug Historical Revenue by Type (2017-2022)
4.2.2 Global Granulomatosis with Polyangiitis Drug Forecasted Revenue by Type (2023-2028)
4.2.3 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2017-2028)
4.3 Global Granulomatosis with Polyangiitis Drug Price by Type
4.3.1 Global Granulomatosis with Polyangiitis Drug Price by Type (2017-2022)
4.3.2 Global Granulomatosis with Polyangiitis Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Granulomatosis with Polyangiitis Drug Sales by Application
5.1.1 Global Granulomatosis with Polyangiitis Drug Historical Sales by Application (2017-2022)
5.1.2 Global Granulomatosis with Polyangiitis Drug Forecasted Sales by Application (2023-2028)
5.1.3 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2017-2028)
5.2 Global Granulomatosis with Polyangiitis Drug Revenue by Application
5.2.1 Global Granulomatosis with Polyangiitis Drug Historical Revenue by Application (2017-2022)
5.2.2 Global Granulomatosis with Polyangiitis Drug Forecasted Revenue by Application (2023-2028)
5.2.3 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2017-2028)
5.3 Global Granulomatosis with Polyangiitis Drug Price by Application
5.3.1 Global Granulomatosis with Polyangiitis Drug Price by Application (2017-2022)
5.3.2 Global Granulomatosis with Polyangiitis Drug Price Forecast by Application (2023-2028)
6 North America
6.1 North America Granulomatosis with Polyangiitis Drug Market Size by Type
6.1.1 North America Granulomatosis with Polyangiitis Drug Sales by Type (2017-2028)
6.1.2 North America Granulomatosis with Polyangiitis Drug Revenue by Type (2017-2028)
6.2 North America Granulomatosis with Polyangiitis Drug Market Size by Application
6.2.1 North America Granulomatosis with Polyangiitis Drug Sales by Application (2017-2028)
6.2.2 North America Granulomatosis with Polyangiitis Drug Revenue by Application (2017-2028)
6.3 North America Granulomatosis with Polyangiitis Drug Market Size by Country
6.3.1 North America Granulomatosis with Polyangiitis Drug Sales by Country (2017-2028)
6.3.2 North America Granulomatosis with Polyangiitis Drug Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Granulomatosis with Polyangiitis Drug Market Size by Type
7.1.1 Europe Granulomatosis with Polyangiitis Drug Sales by Type (2017-2028)
7.1.2 Europe Granulomatosis with Polyangiitis Drug Revenue by Type (2017-2028)
7.2 Europe Granulomatosis with Polyangiitis Drug Market Size by Application
7.2.1 Europe Granulomatosis with Polyangiitis Drug Sales by Application (2017-2028)
7.2.2 Europe Granulomatosis with Polyangiitis Drug Revenue by Application (2017-2028)
7.3 Europe Granulomatosis with Polyangiitis Drug Market Size by Country
7.3.1 Europe Granulomatosis with Polyangiitis Drug Sales by Country (2017-2028)
7.3.2 Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Granulomatosis with Polyangiitis Drug Market Size by Type
8.1.1 Asia Pacific Granulomatosis with Polyangiitis Drug Sales by Type (2017-2028)
8.1.2 Asia Pacific Granulomatosis with Polyangiitis Drug Revenue by Type (2017-2028)
8.2 Asia Pacific Granulomatosis with Polyangiitis Drug Market Size by Application
8.2.1 Asia Pacific Granulomatosis with Polyangiitis Drug Sales by Application (2017-2028)
8.2.2 Asia Pacific Granulomatosis with Polyangiitis Drug Revenue by Application (2017-2028)
8.3 Asia Pacific Granulomatosis with Polyangiitis Drug Market Size by Region
8.3.1 Asia Pacific Granulomatosis with Polyangiitis Drug Sales by Region (2017-2028)
8.3.2 Asia Pacific Granulomatosis with Polyangiitis Drug Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Granulomatosis with Polyangiitis Drug Market Size by Type
9.1.1 Latin America Granulomatosis with Polyangiitis Drug Sales by Type (2017-2028)
9.1.2 Latin America Granulomatosis with Polyangiitis Drug Revenue by Type (2017-2028)
9.2 Latin America Granulomatosis with Polyangiitis Drug Market Size by Application
9.2.1 Latin America Granulomatosis with Polyangiitis Drug Sales by Application (2017-2028)
9.2.2 Latin America Granulomatosis with Polyangiitis Drug Revenue by Application (2017-2028)
9.3 Latin America Granulomatosis with Polyangiitis Drug Market Size by Country
9.3.1 Latin America Granulomatosis with Polyangiitis Drug Sales by Country (2017-2028)
9.3.2 Latin America Granulomatosis with Polyangiitis Drug Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Granulomatosis with Polyangiitis Drug Market Size by Type
10.1.1 Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Type (2017-2028)
10.1.2 Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue by Type (2017-2028)
10.2 Middle East and Africa Granulomatosis with Polyangiitis Drug Market Size by Application
10.2.1 Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Application (2017-2028)
10.2.2 Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue by Application (2017-2028)
10.3 Middle East and Africa Granulomatosis with Polyangiitis Drug Market Size by Country
10.3.1 Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Country (2017-2028)
10.3.2 Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Bionovis SA
11.1.1 Bionovis SA Corporation Information
11.1.2 Bionovis SA Overview
11.1.3 Bionovis SA Granulomatosis with Polyangiitis Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Bionovis SA Granulomatosis with Polyangiitis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bionovis SA Recent Developments
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Corporation Information
11.2.2 Bristol-Myers Squibb Company Overview
11.2.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Bristol-Myers Squibb Company Recent Developments
11.3 ChemoCentryx Inc
11.3.1 ChemoCentryx Inc Corporation Information
11.3.2 ChemoCentryx Inc Overview
11.3.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 ChemoCentryx Inc Recent Developments
11.4 Coherus BioSciences Inc
11.4.1 Coherus BioSciences Inc Corporation Information
11.4.2 Coherus BioSciences Inc Overview
11.4.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Coherus BioSciences Inc Recent Developments
11.5 Genor BioPharma Co Ltd
11.5.1 Genor BioPharma Co Ltd Corporation Information
11.5.2 Genor BioPharma Co Ltd Overview
11.5.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Genor BioPharma Co Ltd Recent Developments
11.6 GlaxoSmithKline Plc
11.6.1 GlaxoSmithKline Plc Corporation Information
11.6.2 GlaxoSmithKline Plc Overview
11.6.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 GlaxoSmithKline Plc Recent Developments
11.7 Iltoo Pharma
11.7.1 Iltoo Pharma Corporation Information
11.7.2 Iltoo Pharma Overview
11.7.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Iltoo Pharma Granulomatosis with Polyangiitis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Iltoo Pharma Recent Developments
11.8 Panacea Biotec Ltd
11.8.1 Panacea Biotec Ltd Corporation Information
11.8.2 Panacea Biotec Ltd Overview
11.8.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Panacea Biotec Ltd Recent Developments
11.9 Sandoz International GmbH
11.9.1 Sandoz International GmbH Corporation Information
11.9.2 Sandoz International GmbH Overview
11.9.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Sandoz International GmbH Recent Developments
11.10 The International Biotechnology Center (IBC) Generium
11.10.1 The International Biotechnology Center (IBC) Generium Corporation Information
11.10.2 The International Biotechnology Center (IBC) Generium Overview
11.10.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 The International Biotechnology Center (IBC) Generium Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Granulomatosis with Polyangiitis Drug Industry Chain Analysis
12.2 Granulomatosis with Polyangiitis Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Granulomatosis with Polyangiitis Drug Production Mode & Process
12.4 Granulomatosis with Polyangiitis Drug Sales and Marketing
12.4.1 Granulomatosis with Polyangiitis Drug Sales Channels
12.4.2 Granulomatosis with Polyangiitis Drug Distributors
12.5 Granulomatosis with Polyangiitis Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Granulomatosis with Polyangiitis Drug Industry Trends
13.2 Granulomatosis with Polyangiitis Drug Market Drivers
13.3 Granulomatosis with Polyangiitis Drug Market Challenges
13.4 Granulomatosis with Polyangiitis Drug Market Restraints
14 Key Findings in The Global Granulomatosis with Polyangiitis Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Granulomatosis with Polyangiitis Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Benralizumab
Table 3. Major Manufacturers of Avacopan
Table 4. Major Manufacturers of Rituximab Biosimilar
Table 5. Major Manufacturers of Others
Table 6. Global Granulomatosis with Polyangiitis Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Granulomatosis with Polyangiitis Drug Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Granulomatosis with Polyangiitis Drug Sales by Region (2017-2022) & (K Pcs)
Table 9. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2017-2022)
Table 10. Global Granulomatosis with Polyangiitis Drug Sales by Region (2023-2028) & (K Pcs)
Table 11. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2023-2028)
Table 12. Global Granulomatosis with Polyangiitis Drug Revenue by Region (2017-2022) & (US$ Million)
Table 13. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2017-2022)
Table 14. Global Granulomatosis with Polyangiitis Drug Revenue by Region (2023-2028) & (US$ Million)
Table 15. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2023-2028)
Table 16. Global Granulomatosis with Polyangiitis Drug Sales by Manufacturers (2017-2022) & (K Pcs)
Table 17. Global Granulomatosis with Polyangiitis Drug Sales Share by Manufacturers (2017-2022)
Table 18. Global Granulomatosis with Polyangiitis Drug Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 19. Global Granulomatosis with Polyangiitis Drug Revenue Share by Manufacturers (2017-2022)
Table 20. Granulomatosis with Polyangiitis Drug Price by Manufacturers (2017-2022) &(USD/Pcs)
Table 21. Global Granulomatosis with Polyangiitis Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Granulomatosis with Polyangiitis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Granulomatosis with Polyangiitis Drug as of 2021)
Table 23. Granulomatosis with Polyangiitis Drug Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Granulomatosis with Polyangiitis Drug Product Offered
Table 25. Date of Manufacturers Enter into Granulomatosis with Polyangiitis Drug Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Granulomatosis with Polyangiitis Drug Sales by Type (2017-2022) & (K Pcs)
Table 28. Global Granulomatosis with Polyangiitis Drug Sales by Type (2023-2028) & (K Pcs)
Table 29. Global Granulomatosis with Polyangiitis Drug Sales Share by Type (2017-2022)
Table 30. Global Granulomatosis with Polyangiitis Drug Sales Share by Type (2023-2028)
Table 31. Global Granulomatosis with Polyangiitis Drug Revenue by Type (2017-2022) & (US$ Million)
Table 32. Global Granulomatosis with Polyangiitis Drug Revenue by Type (2023-2028) & (US$ Million)
Table 33. Global Granulomatosis with Polyangiitis Drug Revenue Share by Type (2017-2022)
Table 34. Global Granulomatosis with Polyangiitis Drug Revenue Share by Type (2023-2028)
Table 35. Granulomatosis with Polyangiitis Drug Price by Type (2017-2022) & (USD/Pcs)
Table 36. Global Granulomatosis with Polyangiitis Drug Price Forecast by Type (2023-2028) & (USD/Pcs)
Table 37. Global Granulomatosis with Polyangiitis Drug Sales by Application (2017-2022) & (K Pcs)
Table 38. Global Granulomatosis with Polyangiitis Drug Sales by Application (2023-2028) & (K Pcs)
Table 39. Global Granulomatosis with Polyangiitis Drug Sales Share by Application (2017-2022)
Table 40. Global Granulomatosis with Polyangiitis Drug Sales Share by Application (2023-2028)
Table 41. Global Granulomatosis with Polyangiitis Drug Revenue by Application (2017-2022) & (US$ Million)
Table 42. Global Granulomatosis with Polyangiitis Drug Revenue by Application (2023-2028) & (US$ Million)
Table 43. Global Granulomatosis with Polyangiitis Drug Revenue Share by Application (2017-2022)
Table 44. Global Granulomatosis with Polyangiitis Drug Revenue Share by Application (2023-2028)
Table 45. Granulomatosis with Polyangiitis Drug Price by Application (2017-2022) & (USD/Pcs)
Table 46. Global Granulomatosis with Polyangiitis Drug Price Forecast by Application (2023-2028) & (USD/Pcs)
Table 47. North America Granulomatosis with Polyangiitis Drug Sales by Type (2017-2022) & (K Pcs)
Table 48. North America Granulomatosis with Polyangiitis Drug Sales by Type (2023-2028) & (K Pcs)
Table 49. North America Granulomatosis with Polyangiitis Drug Revenue by Type (2017-2022) & (US$ Million)
Table 50. North America Granulomatosis with Polyangiitis Drug Revenue by Type (2023-2028) & (US$ Million)
Table 51. North America Granulomatosis with Polyangiitis Drug Sales by Application (2017-2022) & (K Pcs)
Table 52. North America Granulomatosis with Polyangiitis Drug Sales by Application (2023-2028) & (K Pcs)
Table 53. North America Granulomatosis with Polyangiitis Drug Revenue by Application (2017-2022) & (US$ Million)
Table 54. North America Granulomatosis with Polyangiitis Drug Revenue by Application (2023-2028) & (US$ Million)
Table 55. North America Granulomatosis with Polyangiitis Drug Sales by Country (2017-2022) & (K Pcs)
Table 56. North America Granulomatosis with Polyangiitis Drug Sales by Country (2023-2028) & (K Pcs)
Table 57. North America Granulomatosis with Polyangiitis Drug Revenue by Country (2017-2022) & (US$ Million)
Table 58. North America Granulomatosis with Polyangiitis Drug Revenue by Country (2023-2028) & (US$ Million)
Table 59. Europe Granulomatosis with Polyangiitis Drug Sales by Type (2017-2022) & (K Pcs)
Table 60. Europe Granulomatosis with Polyangiitis Drug Sales by Type (2023-2028) & (K Pcs)
Table 61. Europe Granulomatosis with Polyangiitis Drug Revenue by Type (2017-2022) & (US$ Million)
Table 62. Europe Granulomatosis with Polyangiitis Drug Revenue by Type (2023-2028) & (US$ Million)
Table 63. Europe Granulomatosis with Polyangiitis Drug Sales by Application (2017-2022) & (K Pcs)
Table 64. Europe Granulomatosis with Polyangiitis Drug Sales by Application (2023-2028) & (K Pcs)
Table 65. Europe Granulomatosis with Polyangiitis Drug Revenue by Application (2017-2022) & (US$ Million)
Table 66. Europe Granulomatosis with Polyangiitis Drug Revenue by Application (2023-2028) & (US$ Million)
Table 67. Europe Granulomatosis with Polyangiitis Drug Sales by Country (2017-2022) & (K Pcs)
Table 68. Europe Granulomatosis with Polyangiitis Drug Sales by Country (2023-2028) & (K Pcs)
Table 69. Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2017-2022) & (US$ Million)
Table 70. Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2023-2028) & (US$ Million)
Table 71. Asia Pacific Granulomatosis with Polyangiitis Drug Sales by Type (2017-2022) & (K Pcs)
Table 72. Asia Pacific Granulomatosis with Polyangiitis Drug Sales by Type (2023-2028) & (K Pcs)
Table 73. Asia Pacific Granulomatosis with Polyangiitis Drug Revenue by Type (2017-2022) & (US$ Million)
Table 74. Asia Pacific Granulomatosis with Polyangiitis Drug Revenue by Type (2023-2028) & (US$ Million)
Table 75. Asia Pacific Granulomatosis with Polyangiitis Drug Sales by Application (2017-2022) & (K Pcs)
Table 76. Asia Pacific Granulomatosis with Polyangiitis Drug Sales by Application (2023-2028) & (K Pcs)
Table 77. Asia Pacific Granulomatosis with Polyangiitis Drug Revenue by Application (2017-2022) & (US$ Million)
Table 78. Asia Pacific Granulomatosis with Polyangiitis Drug Revenue by Application (2023-2028) & (US$ Million)
Table 79. Asia Pacific Granulomatosis with Polyangiitis Drug Sales by Region (2017-2022) & (K Pcs)
Table 80. Asia Pacific Granulomatosis with Polyangiitis Drug Sales by Region (2023-2028) & (K Pcs)
Table 81. Asia Pacific Granulomatosis with Polyangiitis Drug Revenue by Region (2017-2022) & (US$ Million)
Table 82. Asia Pacific Granulomatosis with Polyangiitis Drug Revenue by Region (2023-2028) & (US$ Million)
Table 83. Latin America Granulomatosis with Polyangiitis Drug Sales by Type (2017-2022) & (K Pcs)
Table 84. Latin America Granulomatosis with Polyangiitis Drug Sales by Type (2023-2028) & (K Pcs)
Table 85. Latin America Granulomatosis with Polyangiitis Drug Revenue by Type (2017-2022) & (US$ Million)
Table 86. Latin America Granulomatosis with Polyangiitis Drug Revenue by Type (2023-2028) & (US$ Million)
Table 87. Latin America Granulomatosis with Polyangiitis Drug Sales by Application (2017-2022) & (K Pcs)
Table 88. Latin America Granulomatosis with Polyangiitis Drug Sales by Application (2023-2028) & (K Pcs)
Table 89. Latin America Granulomatosis with Polyangiitis Drug Revenue by Application (2017-2022) & (US$ Million)
Table 90. Latin America Granulomatosis with Polyangiitis Drug Revenue by Application (2023-2028) & (US$ Million)
Table 91. Latin America Granulomatosis with Polyangiitis Drug Sales by Country (2017-2022) & (K Pcs)
Table 92. Latin America Granulomatosis with Polyangiitis Drug Sales by Country (2023-2028) & (K Pcs)
Table 93. Latin America Granulomatosis with Polyangiitis Drug Revenue by Country (2017-2022) & (US$ Million)
Table 94. Latin America Granulomatosis with Polyangiitis Drug Revenue by Country (2023-2028) & (US$ Million)
Table 95. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Type (2017-2022) & (K Pcs)
Table 96. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Type (2023-2028) & (K Pcs)
Table 97. Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue by Type (2017-2022) & (US$ Million)
Table 98. Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue by Type (2023-2028) & (US$ Million)
Table 99. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Application (2017-2022) & (K Pcs)
Table 100. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Application (2023-2028) & (K Pcs)
Table 101. Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue by Application (2017-2022) & (US$ Million)
Table 102. Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue by Application (2023-2028) & (US$ Million)
Table 103. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Country (2017-2022) & (K Pcs)
Table 104. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Country (2023-2028) & (K Pcs)
Table 105. Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue by Country (2017-2022) & (US$ Million)
Table 106. Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue by Country (2023-2028) & (US$ Million)
Table 107. Bionovis SA Corporation Information
Table 108. Bionovis SA Description and Major Businesses
Table 109. Bionovis SA Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 110. Bionovis SA Granulomatosis with Polyangiitis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Bionovis SA Recent Developments
Table 112. Bristol-Myers Squibb Company Corporation Information
Table 113. Bristol-Myers Squibb Company Description and Major Businesses
Table 114. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 115. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Bristol-Myers Squibb Company Recent Developments
Table 117. ChemoCentryx Inc Corporation Information
Table 118. ChemoCentryx Inc Description and Major Businesses
Table 119. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 120. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. ChemoCentryx Inc Recent Developments
Table 122. Coherus BioSciences Inc Corporation Information
Table 123. Coherus BioSciences Inc Description and Major Businesses
Table 124. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 125. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Coherus BioSciences Inc Recent Developments
Table 127. Genor BioPharma Co Ltd Corporation Information
Table 128. Genor BioPharma Co Ltd Description and Major Businesses
Table 129. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 130. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Genor BioPharma Co Ltd Recent Developments
Table 132. GlaxoSmithKline Plc Corporation Information
Table 133. GlaxoSmithKline Plc Description and Major Businesses
Table 134. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 135. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. GlaxoSmithKline Plc Recent Developments
Table 137. Iltoo Pharma Corporation Information
Table 138. Iltoo Pharma Description and Major Businesses
Table 139. Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 140. Iltoo Pharma Granulomatosis with Polyangiitis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Iltoo Pharma Recent Developments
Table 142. Panacea Biotec Ltd Corporation Information
Table 143. Panacea Biotec Ltd Description and Major Businesses
Table 144. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 145. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Panacea Biotec Ltd Recent Developments
Table 147. Sandoz International GmbH Corporation Information
Table 148. Sandoz International GmbH Description and Major Businesses
Table 149. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 150. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Sandoz International GmbH Recent Developments
Table 152. The International Biotechnology Center (IBC) Generium Corporation Information
Table 153. The International Biotechnology Center (IBC) Generium Description and Major Businesses
Table 154. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 155. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. The International Biotechnology Center (IBC) Generium Recent Developments
Table 157. Key Raw Materials Lists
Table 158. Raw Materials Key Suppliers Lists
Table 159. Granulomatosis with Polyangiitis Drug Distributors List
Table 160. Granulomatosis with Polyangiitis Drug Customers List
Table 161. Granulomatosis with Polyangiitis Drug Market Trends
Table 162. Granulomatosis with Polyangiitis Drug Market Drivers
Table 163. Granulomatosis with Polyangiitis Drug Market Challenges
Table 164. Granulomatosis with Polyangiitis Drug Market Restraints
Table 165. Research Programs/Design for This Report
Table 166. Key Data Information from Secondary Sources
Table 167. Key Data Information from Primary Sources
List of Figures
Figure 1. Granulomatosis with Polyangiitis Drug Product Picture
Figure 3. Global Granulomatosis with Polyangiitis Drug Market Share by Type in 2021 & 2028
Figure 3. Benralizumab Product Picture
Figure 4. Avacopan Product Picture
Figure 5. Rituximab Biosimilar Product Picture
Figure 6. Others Product Picture
Figure 7. Global Granulomatosis with Polyangiitis Drug Market Share by Application in 2021 & 2028
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Others
Figure 11. Granulomatosis with Polyangiitis Drug Report Years Considered
Figure 12. Global Granulomatosis with Polyangiitis Drug Sales 2017-2028 (K Pcs)
Figure 13. Global Granulomatosis with Polyangiitis Drug Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Granulomatosis with Polyangiitis Drug Revenue 2017-2028 (US$ Million)
Figure 15. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 16. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2017-2022)
Figure 17. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2023-2028)
Figure 18. North America Granulomatosis with Polyangiitis Drug Sales YoY (2017-2028) & (K Pcs)
Figure 19. North America Granulomatosis with Polyangiitis Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 20. Europe Granulomatosis with Polyangiitis Drug Sales YoY (2017-2028) & (K Pcs)
Figure 21. Europe Granulomatosis with Polyangiitis Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 22. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales YoY (2017-2028) & (K Pcs)
Figure 23. Asia-Pacific Granulomatosis with Polyangiitis Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Latin America Granulomatosis with Polyangiitis Drug Sales YoY (2017-2028) & (K Pcs)
Figure 25. Latin America Granulomatosis with Polyangiitis Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 26. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales YoY (2017-2028) & (K Pcs)
Figure 27. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 28. The Granulomatosis with Polyangiitis Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 29. The Top 5 and 10 Largest Manufacturers of Granulomatosis with Polyangiitis Drug in the World: Market Share by Granulomatosis with Polyangiitis Drug Revenue in 2021
Figure 30. Global Granulomatosis with Polyangiitis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 31. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2017-2028)
Figure 32. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2017-2028)
Figure 33. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2017-2028)
Figure 34. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2017-2028)
Figure 35. North America Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2017-2028)
Figure 36. North America Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2017-2028)
Figure 37. North America Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2017-2028)
Figure 38. North America Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2017-2028)
Figure 39. North America Granulomatosis with Polyangiitis Drug Sales Share by Country (2017-2028)
Figure 40. North America Granulomatosis with Polyangiitis Drug Revenue Share by Country (2017-2028)
Figure 41. U.S. Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 42. Canada Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 43. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2017-2028)
Figure 44. Europe Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2017-2028)
Figure 45. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2017-2028)
Figure 46. Europe Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2017-2028)
Figure 47. Europe Granulomatosis with Polyangiitis Drug Sales Share by Country (2017-2028)
Figure 48. Europe Granulomatosis with Polyangiitis Drug Revenue Share by Country (2017-2028)
Figure 49. Germany Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 50. France Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 51. U.K. Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 52. Italy Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 53. Russia Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 54. Asia Pacific Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2017-2028)
Figure 55. Asia Pacific Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2017-2028)
Figure 56. Asia Pacific Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2017-2028)
Figure 57. Asia Pacific Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2017-2028)
Figure 58. Asia Pacific Granulomatosis with Polyangiitis Drug Sales Share by Region (2017-2028)
Figure 59. Asia Pacific Granulomatosis with Polyangiitis Drug Revenue Share by Region (2017-2028)
Figure 60. China Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 61. Japan Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 62. South Korea Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 63. India Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 64. Australia Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 65. Taiwan Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 66. Indonesia Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 67. Thailand Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 68. Malaysia Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 69. Philippines Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 70. Latin America Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2017-2028)
Figure 71. Latin America Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2017-2028)
Figure 72. Latin America Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2017-2028)
Figure 73. Latin America Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2017-2028)
Figure 74. Latin America Granulomatosis with Polyangiitis Drug Sales Share by Country (2017-2028)
Figure 75. Latin America Granulomatosis with Polyangiitis Drug Revenue Share by Country (2017-2028)
Figure 76. Mexico Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 77. Brazil Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 78. Argentina Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 79. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2017-2028)
Figure 80. Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2017-2028)
Figure 81. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2017-2028)
Figure 82. Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2017-2028)
Figure 83. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Share by Country (2017-2028)
Figure 84. Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue Share by Country (2017-2028)
Figure 85. Turkey Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 86. Saudi Arabia Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 87. U.A.E Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (US$ Million)
Figure 88. Granulomatosis with Polyangiitis Drug Value Chain
Figure 89. Granulomatosis with Polyangiitis Drug Production Process
Figure 90. Channels of Distribution
Figure 91. Distributors Profiles
Figure 92. Bottom-up and Top-down Approaches for This Report
Figure 93. Data Triangulation
Figure 94. Key Executives Interviewed
Industry Market Size
